Fujifilm Launches the Velocity MRI System at RSNA 2021
The brand new system is a high performance, high-field scanner coupled with the clinical and comfort advantages of open MRI
Lexington, Mass., USA, Nov. 29, 2021 (GLOBE NEWSWIRE) — FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic imaging and medical informatics solutions, announced it will unveil the Velocity MRI System, its advanced, high-field open MRI system during the 2021 Radiological Society of North America (RSNA) conference, booth #1911 (South Hall), from November 28 – December 2, 2021 at McCormick Place in Chicago.
The Velocity MRI system is Fujifilm’s newest MRI scanner, designed to streamline workflow and enhance the patient experience with its unique open gantry, integrated radiofrequency (RF) coils and reconstruction technologies. The system’s anatomy-conformable Synergy Flex coil is the first of its kind for an open, vertical field MRI scanner, promoting fast abdominal and orthopedic imaging.
“Velocity defines what today’s true Open MRI is about – the unique patient comfort and accommodation benefits of open-sided MRI now joined by the workflow and image quality benefits of integrated RF coils and enhanced reconstruction technologies,” said Shawn Etheridge, Director, CT and MRI Marketing for FUJIFILM Healthcare Americas Corporation. “We now offer a scanner that can differentiate a hospital or outpatient imaging service, while delivering outstanding image quality, short exam times and operator ease-of-use benefits.”
The scanner’s unique, open gantry creates a spacious feeling for claustrophobic, bariatric, geriatric and pediatric patients. Additionally, the Velocity’s open-sided gantry provides easy patient access for real-time interventional procedures. The Velocity’s extra-wide patient table can accommodate patients up to 660 pounds, and offers in-gantry left and right movement with multiple coil connectors for easy patient positioning.
To learn more about Fujifilm’s Velocity MRI system, request a virtual or in-person demo at RSNA here.
About Fujifilm
FUJIFILM Healthcare Americas Corporation is a leading innovator in diagnostic and enterprise imaging solutions designed to meet the evolving needs of healthcare across prevention, diagnosis, and treatment. Fujifilm’s medical imaging portfolio includes solutions for digital radiography, mammography, computed tomography, magnetic resonance imaging, ultrasound, endoscopy, and endosurgery. The Synapse® Enterprise Imaging portfolio provides healthcare professionals with the imaging and data access needed to deliver a complete patient record. REiLI®, Fujifilm’s artificial intelligence initiative, combines Fujifilm’s rich image -processing heritage with cutting-edge AI innovations to inspire a new tier of clinical confidence. The In-Vitro Diagnostic portfolio provides the golden standard of molecular based immunoassay technology for liver surveillance, cutting edge clinical diagnostic chemicals for leading laboratories across the country and diagnostic chemicals for OEM white labeling products. The company is headquartered in Lexington, Massachusetts. For more information please visit healthcaresolutions-us.fujifilm.com.
FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com
Attachment
CONTACT: Marissa Confredo Fujifilm 914-343-4761 [email protected]
Disclaimer: This content is distributed by The GlobeNewswire
